Tag

Right To Try

All articles tagged with #right to try

Sasse laments Congress’s theatrics as AI reshapes the national agenda
politics2 months ago

Sasse laments Congress’s theatrics as AI reshapes the national agenda

Former Sen. Ben Sasse, battling stage-four pancreatic cancer, argues in a CBS interview and town hall that Congress is trapped in tribalism and is failing to tackle big, long-term challenges like the AI revolution and the future of work. He calls for a larger House, a more deliberative Senate, and broader access to experimental treatments via patient- and provider-driven decisions. He credits prayer, providence and an experimental drug for extending his life and urges Americans to discuss mortality, family, and grand questions at home to strengthen a republic built on humility and deliberation.

Trump signs order to fast-track psychedelic research, including ibogaine
politics2 months ago

Trump signs order to fast-track psychedelic research, including ibogaine

President Trump signed an executive order to ease federal restrictions on psychedelic research, including ibogaine, with a $50 million funding commitment and a pathway for ibogaine to be studied and used under the FDA's Right To Try for seriously ill patients. The FDA will also add three psychedelics to the National Priority Voucher program to accelerate reviews, while maintaining oversight and not legalizing the drugs. The move aims to spur new mental-health treatments but underscores safety concerns and the need for more robust clinical trials.

White House Accelerates Psychedelic Therapies to Tackle Serious Mental Illness
politics2 months ago

White House Accelerates Psychedelic Therapies to Tackle Serious Mental Illness

The White House issues a policy order to speed up research, review, and potential approval of psychedelic medicines (including ibogaine) for serious mental illnesses, expanding access through Right to Try pathways, prioritizing FDA reviews for Breakthrough Therapy-designated drugs, funding federal-state collaboration, and boosting data sharing with the VA and private sector, while pursuing timely rescheduling of Schedule I substances after Phase 3 trials — all within existing laws and funding constraints, with a focus on veterans and reducing suicidality.